🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Ovarian Germ Cell Cancer

68Ga-SorB PET/CT Imaging in Patients With Solid Tumors NCT07760012NA1 site📍 Beijing Peking University Third Hospital · Tests: 68Ga-SorB PET/CT Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies NCT04282044Phase 13 sites📍 Scottsdale📍 La Jolla📍 Stanford BioEclipse Therapeutics · Tests: CRX100 suspension for infusion, Fludarabine, Cyclophosphamide TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors NCT02429687Phase 31 site📍 Jinan Beihua Kong · Tests: Paclitaxel, Carboplatin, Bleomycin, Etoposide, Cisplatin A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors NCT07749586Phase 1, Phase 24 sites📍 New York📍 Huntersville📍 San Antonio Arvinas Inc. · Tests: ARV-6723, Pembrolizumab, SOC Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors NCT03067181Phase 3629 sites📍 Birmingham📍 Mobile📍 Anchorage Children's Oncology Group · Tests: Best Practice, Biopsy Procedure, Biospecimen Collection, Bleomycin Sulfate, Carboplatin ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors NCT03686124Phase 1, Phase 221 sites📍 Stanford📍 Aurora📍 Miami Immatics US, Inc. · Tests: IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product, Nivolumab, IMADetect® A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors NCT04895709Phase 1, Phase 247 sites📍 Clovis📍 Los Angeles📍 Newport Beach Bristol-Myers Squibb · Tests: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig IDOV-Immune for Advanced Solid Tumors NCT06910657Phase 15 sites📍 St Louis📍 Houston📍 San Antonio ViroMissile, Inc. · Tests: IDOV-Immune (oncolytic vaccinia virus) IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel, Capivasertib Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers NCT05296564Phase 1, Phase 21 site📍 Jerusalem Hadassah Medical Organization · Tests: CYCLOPHOSPHAMIDE and FLUDARABIN, Cyclophosphamide, HBI 0201-ESO TCRT, Aldesleukin DBC-664 in Adult Patients With Solid Tumors NCT07705035Phase 16 sites📍 Denver📍 Grand Rapids📍 East Brunswick Duboce Biopharmaceuticals, Inc. · Tests: DBC-664 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection NCT06503146Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: [18F]FAPI-74, [18F]FDG Ovarian Reserve and Semen Parameters Evolution During Adjuvant Therapy in Melanoma NCT05429138n/a12 sites📍 Bordeaux📍 Marseille📍 Marseille Assistance Publique Hopitaux De Marseille · Tests: biological sampling Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring NCT05500391Phase 23 sites📍 Amiens📍 Caen📍 Lille Centre Oscar Lambret · Tests: Oncological Follow-up Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies NCT05417594Phase 1, Phase 232 sites📍 La Jolla📍 Los Angeles📍 San Francisco AstraZeneca · Tests: AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391, Trastuzumab Deruxtecan (T-DXd), Datopotamab Deruxtecan (Dato-DXd) Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors NCT07523529Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Autologous dual-target CAR-T cells selected from the predefined target library., Fludarabine, Cyclophosphamide Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors NCT06276491Phase 127 sites📍 Duarte📍 Palo Alto📍 San Francisco Xencor, Inc. · Tests: XmAb541 IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma NCT07138222n/a6 sites📍 Sydney📍 Brisbane📍 Cairns Peter MacCallum Cancer Centre, Australia The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas NCT07285044Phase 21 site📍 Jacksonville Mayo Clinic · Tests: Cancer Therapeutic Procedure, Cancer Therapeutic Procedure, Questionnaire Administration A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors NCT05914116Phase 1, Phase 2107 sites📍 Tucson📍 Los Angeles📍 Los Angeles DualityBio Inc. · Tests: DB-1311, Lopinavir and Ritonavir Tablets, itraconazole, Enzalutamide, Abiraterone Integrated Cancer Repository for Cancer Research NCT02012699n/a42 sites📍 Greenwood Village📍 Manchester📍 Daytona Beach University of Nebraska EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors NCT07410676Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EBNK-001 + IL-15 + Pembrolizumab Familial Investigations of Childhood Cancer Predisposition NCT03050268n/a1 site📍 Memphis St. Jude Children's Research Hospital ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation NCT05059444n/a57 sites📍 Birmingham📍 Chandler📍 Hot Springs Guardant Health, Inc. · Tests: Guardant Reveal Navigation Intervention for Adolescent and Young Adult Cancer Survivors NCT07406087NA1 site📍 Pasadena Kaiser Permanente · Tests: Adapted patient navigation program targeting adolescent and young adult cancer survivors Sample Collection for Ongoing Research and Product Evaluation Study NCT07318051n/a1 site📍 Austin Natera, Inc. Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors NCT03755739Phase 2, Phase 31 site📍 Guanzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470Phase 112 sites📍 Los Angeles📍 Grand Rapids📍 Lake Success MacroGenics · Tests: MGC026 Dose Escalation, MGC026 Dose for Expansion A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer NCT03412877Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Cyclophosphamide, Fludarabine, Aldesleukin, Individual Patient TCR-Transduced PBL, Pembrolizumab (KEYTRUDA(R))
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy